|
1
|
Global Burden of Disease Cancer
Collaboration; Fitzmaurice C, Abate D, Abbasi N, Abbastabar H,
Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I,
et al: Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2017:
A systematic analysis for the global burden of disease study. JAMA
Oncol. 5:1749–1768. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma MC, Chen YY, Li SH, Cheng YF, Wang CC,
Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, et al: Intra-arterial
chemotherapy with doxorubicin and cisplatin is effective for
advanced hepatocellular cell carcinoma. ScientificWorldJournal.
2014:1601382014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bruix J, Reig M and Sherman M:
Evidence-based diagnosis, staging, and treatment of patients with
hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan
XY: CD133+ HCC cancer stem cells confer chemoresistance by
preferential expression of the Akt/PKB survival pathway. Oncogene.
27:1749–1758. 2008. View Article : Google Scholar
|
|
6
|
Schuller AP, Wu CC, Dever TE, Buskirk AR
and Green R: eIF5A functions globally in translation elongation and
termination. Mol Cell. 66:194–205.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taylor CA, Zheng Q, Liu Z and Thompson JE:
Role of p38 and JNK MAPK signaling pathways and tumor suppressor
p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung
cancer cells. Mol Cancer. 12:352013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mathews MB and Hershey JW: The translation
factor eIF5A and human cancer. Biochim Biophys Acta. 1849:836–844.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Caraglia M, Park MH, Wolff EC, Marra M and
Abbruzzese A: eIF5A isoforms and cancer: Two brothers for two
functions? Amino Acids. 44:103–109. 2013. View Article : Google Scholar :
|
|
10
|
Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ,
Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, et al: Overexpression
of EIF5A2 promotes colorectal carcinoma cell aggres-siveness by
upregulating MTA1 through C-myc to induce
epithelial-mesenchymaltransition. Gut. 61:562–575. 2012. View Article : Google Scholar
|
|
11
|
Yang J, Yu H, Shen M, Wei W, Xia L and
Zhao P: N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer
cells to doxorubicin by preventing epithelial-mesenchymal
transition through inhibition of eukaryotic translation initiation
factor 5A2 activation. Cancer Sci. 105:219–227. 2014. View Article : Google Scholar
|
|
12
|
Khosravi S, Wong RP, Ardekani GS, Zhang G,
Martinka M, Ong CJ and Li G: Role of EIF5A2, a downstream target of
Akt, in promoting melanoma cell invasion. Br J Cancer. 110:399–408.
2014. View Article : Google Scholar :
|
|
13
|
Meng QB, Kang WM, Yu JC, Liu YQ, Ma ZQ,
Zhou L, Cui QC and Zhou WX: Overexpression of eukaryotic
translation initiation factor 5A2 (EIF5A2) correlates with cell
aggressiveness and poor survival in gastric cancer. PLoS One.
10:e01192292015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yao M, Hong Y, Liu Y, Chen W and Wang W:
N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of
pancreatic ductal adenocarcinoma cells to gemcitabine via the
inhibition of eukaryotic translation initiation factor 5A2. Exp
Ther Med. 14:2101–2107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Levy JMM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding ZB, Hui B, Shi YH, Zhou J, Peng YF,
Gu CY, Yang H, Shi GM, Ke AW, Wang XY, et al: Autophagy activation
in hepatocellular carcinoma contributes to the tolerance of
oxaliplatin via reactive oxygen species modulation. Clin Cancer
Res. 17:6229–6238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hayat MA: Autophagy: Cancer, other
pathologies, inflammation, immunity, infection, and aging. 1. 1st
edition. Elsevier; Academic Press; 2016
|
|
18
|
Pohl C and Dikic I: Cellular quality
control by the ubiquitin-proteasome system and autophagy. Science.
366:818–822. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu F, Zhao Y, Yu Y, Fang JM, Cui R, Liu
ZQ, Guo XL and Xu Q: Docetaxel-mediated autophagy promotes
chemoresistance in castration-resistant prostate cancer cells by
inhibiting STAT3. Cancer Lett. 416:24–30. 2018. View Article : Google Scholar
|
|
20
|
Piya S, Andreeff M and Borthakur G:
Targeting autophagy to overcome chemoresistance in acute
myleogenous leukemia. Autophagy. 13:214–215. 2017. View Article : Google Scholar :
|
|
21
|
Zeng Q, Liu J, Cao P, Li J, Liu X, Fan X,
Liu L, Cheng Y, Xiong W, Li J, et al: Inhibition of REDD1
sensitizes bladder urothelial carcinoma to paclitaxel by inhibiting
autophagy. Clin Cancer Res. 24:445–459. 2018. View Article : Google Scholar
|
|
22
|
Fulda S and Kogel D: Cell death by
autophagy: Emerging molecular mechanisms and implications for
cancer therapy. Oncogene. 34:5105–5113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Lu Q, Cheng S, Wang X and Zhang H:
Autophagy activity contributes to programmed cell death in
Caenorhabditis elegans. Autophagy. 9:1975–1982. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Wei S, Zhao Y, Shi C, Liu P, Zhang
C, Lei Y, Zhang B, Bai B, Huang Y and Zhang H: Anti-proliferation
of breast cancer cells with itraconazole: Hedgehog pathway
inhibition induces apoptosis and autophagic cell death. Cancer
Lett. 385:128–136. 2017. View Article : Google Scholar
|
|
25
|
Segala G, David M, de Medina P, Poirot MC,
Serhan N, Vergez F, Mougel A, Saland E, Carayon K, Leignadier J, et
al: Dendrogenin A drives LXR to trigger lethal autophagy in
cancers. Nat Commun. 8:19032017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masui A, Hamada M, Kameyama H, Wakabayashi
K, Takasu A, Imai T, Iwai S and Yura Y: Autophagy as a survival
mechanism for squamous cell carcinoma cells in endonuclease
G-mediated apoptosis. PLoS One. 11:e01627862016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kun Z, Hanqing G, Hailing T, Yuan Y, Jun
Z, Lingxia Z, Kun H and Xin Z: Gastrin enhances autophagy and
promotes gastric carcinoma proliferation via inducing AMPKα. Oncol
Res. 25:1399–1407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altman JK, Szilard A, Goussetis DJ,
Sassano A, Colamonici M, Gounaris E, Frankfurt O, Giles FJ, Eklund
EA, Beauchamp EM and Platanias LC: Autophagy is a survival
mechanism of acute myelogenous leukemia precursors during dual
mTORC2/mTORC1 targeting. Clin Cancer Res. 20:2400–2409. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu Q, Deng J, Fan D, Duan Z, Zhu C, Fu R
and Wang S: Ginsenoside Rh4 induces apoptosis and autophagic cell
death through activation of the ROS/JNK/p53 pathway in colorectal
cancer cells. Biochem Pharmacol. 148:64–74. 2018. View Article : Google Scholar
|
|
30
|
Sun D, Zhu L, Zhao Y, Jiang Y, Chen L, Yu
Y and Ouyang L: Fluoxetine induces autophagic cell death via
eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer.
Cell Prolif. 51:e124022018. View Article : Google Scholar
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
32
|
Yamakawa K, Nakano-Narusawa Y, Hashimoto
N, Yokohira M and Matsuda Y: Development and clinical trials of
nucleic acid medicines for pancreatic cancer treatment. Int J Mol
Sci. 20:42242019. View Article : Google Scholar :
|
|
33
|
Behlke MA: Chemical modification of siRNAs
for in vivo use. Oligonucleotides. 18:305–319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Y, Du F, Chen W, Yao M, Lv K and Fu P:
EIF5A2 is a novel chemoresistance gene in breast cancer. Breast
Cancer. 22:602–607. 2015. View Article : Google Scholar
|
|
35
|
Sun J, Xu Z, Lv H, Wang Y, Wang L, Ni Y,
Wang X, Hu C, Chen S, Teng F, et al: eIF5A2 regulates the
resistance of gastric cancer cells to cisplatin via induction of
EMT. Am J Transl Res. 10:4269–4279. 2018.
|
|
36
|
Zheng X, Gao L, Wang BT, Shen P, Yuan XF,
Zhang LQ, Yang L, Zhang DP, Zhang Q and Wang XM: Overexpression of
EIF5A2 is associated with poor survival and aggressive tumor
biology in gallbladder cancer. Histol Histopathol. 35:579–587.
2020.
|
|
37
|
Huang PY, Zeng TT, Ban X, Li MQ, Zhang BZ,
Zhu YH, Hua WF, Mai HQ, Zhang L, Guan XY and Li Y: Expression of
EIF5A2 associates with poor survival of nasopharyngeal carcinoma
patients treated with induction chemotherapy. BMC Cancer.
16:6692016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Y, Fu L, Li JB, Qin Y, Zeng TT, Zhou J,
Zeng ZL, Chen J, Cao TT, Ban X, et al: Increased expression of
EIF5A2, via hypoxia or gene amplification, contributes to
metastasis and angiogenesis of esophageal squamous cell carcinoma.
Gastroenterology. 146:1701–1713.e9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xue F, Liu Y, Chu H, Wen Y, Yan L, Tang Q,
Xiao E, Zhang D and Zhang H: eIF5A2 is an alternative pathway for
cell proliferation in cetuximab-treated epithelial hepatocellular
carcinoma. Am J Transl Res. 8:4670–4681. 2016.PubMed/NCBI
|
|
40
|
Fang L, Gao L, Xie L and Xiao G:
Eukaryotic translation initiation factor 5A-2 involves in
doxorubicin-induced epithelial-mesenchymal transition in oral
squamous cell carcinoma cells. J Cancer. 9:3479–3488. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bao Y, Lu Y, Wang X, Feng W, Sun X, Guo H,
Tang C, Zhang X, Shi Q and Yu H: Eukaryotic translation initiation
factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer
through epithelial mesenchymal transition. Cancer Cell Int.
15:1092015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang H, Li XD, Zhou Y, Ban X, Zeng TT, Li
L, Zhang BZ, Yun J, Xie D, Guan XY and Li Y: Stemness and
chemotherapeutic drug resistance induced by EIF5A2 overexpression
in esophageal squamous cell carcinoma. Oncotarget. 6:26079–26089.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen C, Lu L, Yan S, Yi H, Yao H, Wu D, He
G, Tao X and Deng X: Autophagy and doxorubicin resistance in
cancer. Anticancer Drugs. 29:1–9. 2018. View Article : Google Scholar
|
|
44
|
Li L, Wang Y, Jiao L, Lin C, Lu C, Zhang
K, Hu C, Ye J, Zhang D, Wu H, et al: Protective autophagy decreases
osimertinib cytotoxicity through regulation of stem cell-like
properties in lung cancer. Cancer Lett. 452:191–202. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dai CH, Shu Y, Chen P, Wu JN, Zhu LH, Yuan
RX, Long WG, Zhu YM and Li J: YM155 sensitizes non-small cell lung
cancer cells to EGFR-tyrosine kinase inhibitors through the
mechanism of autophagy induction. Biochim Biophys Acta Mol Basis
Dis. 1864:3786–3798. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS,
Cheng AL, Chen PJ and Chen KF: Mcl-1-dependent activation of Beclin
1 mediates autophagic cell death induced by sorafenib and SC-59 in
hepatocellular carcinoma cells. Cell Death Dis. 4:e4852013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu FQ, Fang T, Yu LX, Lv GS, Lv HW, Liang
D, Li T, Wang CZ, Tan YX, Ding J, et al: ADRB2 signaling promotes
HCC progression and sorafenib resistance by inhibiting autophagic
degradation of HIF1alpha. J Hepatol. 65:314–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liang XH, Kleeman LK, Jiang HH, Gordon G,
Goldman JE, Berry G, Herman B and Levine B: Protection against
fatal Sindbis virus encephalitis by beclin, a novel
Bcl-2-interacting protein. J Virol. 72:8586–8596. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guo QQ, Wang SS, Zhang SS, Xu HD, Li XM,
Guan Y, Yi F, Zhou TT, Jiang B, Bai N, et al: ATM-CHK2-Beclin 1
axis promotes autophagy to maintain ROS homeostasis under oxidative
stress. EMBO J. 39:e1031112020. View Article : Google Scholar : PubMed/NCBI
|
